News
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
31 Jan 23
Biotech, News, Small Cap, FDA, Top Stories, General
The Latest Analyst Ratings for Travere Therapeutics
30 Jan 23
Analyst Ratings
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $40
30 Jan 23
News, Price Target, Analyst Ratings
Piper Sandler Maintains Overweight on Travere Therapeutics, Raises Price Target to $42
11 Jan 23
News, Price Target, Analyst Ratings
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
14 Dec 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Stifel Initiates Coverage On Travere Therapeutics with Hold Rating, Announces Price Target of $22
14 Dec 22
News, Price Target, Initiation, Analyst Ratings
Stocks That Hit 52-Week Lows On Monday
12 Dec 22
Options
4 Analysts Have This to Say About Travere Therapeutics
5 Dec 22
Analyst Ratings
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
5 Dec 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Where Travere Therapeutics Stands With Analysts
5 Dec 22
Analyst Ratings
Wells Fargo Initiates Coverage On Travere Therapeutics with Overweight Rating, Announces Price Target of $28
5 Dec 22
News, Price Target, Initiation, Analyst Ratings
Stocks That Hit 52-Week Lows On Tuesday
22 Nov 22
News, Options
Press releases
Travere Therapeutics to Present at Upcoming Investor Conferences
8 Feb 23
News, Press Releases
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Jan 23
Press Releases
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
3 Jan 23
News, Press Releases
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 Dec 22
Press Releases
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 Nov 22
Markets, Press Releases